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impacts in children and is currently being evaluated for use in adults in  
the Czech Republic (CR). The objective of this study was to assess the  
cost-effectiveness of pneumococcal vaccination strategies in the elderly 
population. METHODS: A first-order Markov decision-analytic model was 
developed to compare cost-effectiveness of vaccination with PCV13, PPSV23  
and no vaccination in the Czech Republic. PPSV23 effectiveness was derived 
from literature and PCV13 was extrapolated from impact in children adjusting 
for immunosenescence in older persons. Pneumonia, bacteremia and meningitis 
hospitalization and cost data were acquired from health authorities and  
DRG system in CR; outpatient data were based on retrospective patient survey. 
The model used a lifetime time horizon and 3% discount rate. RESULTS:  
Used according to Czech guidelines, PCV13 vaccination is associated with 0.0002 
life-years gained for an additional EUR 1.002 on average (EUR 3,812,478 in total) 
compared to no vaccination and 0.0004 life-years gained for additional EUR 0.97 
on average (EUR 3,704,061 in total) compared to PPSV23. This leads to an ICER  
of EUR/LYG 4,950 and 2,265 under current reimbursement. If all moderate  
and high risk people were vaccinated, the ICER would increase to EUR/LYG 5,582 
and 6,691, respectively, under current reimbursement and to ICER of EUR/LYG 
8,676 and 7,057 under full reimbursement. CONCLUSIONS: Confronting  
the national GDP per capita with the WHO recommendation on health care 
spending per QALY gained, PCV13 national immunization program in the Czech 




COST IMPACT OF A COMPREHENSIVE STI SCREENING STRATEGY,  
INCLUDING CHLAMYDIA, GONORRHEA AND TRICHOMONIASIS: A US PAYER 
PERSPECTIVE  
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OBJECTIVES: Chlamydia (CT), gonorrhea (GC) and trichomoniasis (TV) screening 
can be conducted simultaneously on a single sample using nucleic acid 
amplification testing (NAAT). NAAT has made screening faster and more 
sensitive. Targeted CT/GC screening has long been supported by clinical 
guidelines (USPSTF, CDC, and ACOG) and research has shown screening to be 
cost-effective from a health-system perspective. Despite this, testing rates are 
low (estimated at 38% by the CDC). Here, we explore the clinical and economic 
impact of increasing adherence to screening guidelines for CT/GC and the 
introduction of TV screening from a US payer perspective. METHODS: A 
decision-tree cost-impact model was developed to compare current screening 
rates for CT/GC with a hypothetical increase in CT/GC screening uptake and the 
addition of TV screening in women 15-24yrs. with high-risk sexual behavior. 
Model components included testing, treatment, confirmation of eradication, and 
adverse events for women 15-24. Inputs were based on published literature. The 
model examines member cost (excluding partner transmission) and clinical 
impact of an increase in screening uptake over 1 year. RESULTS: For a 
hypothetical member population of 5.0M, with a baseline CT/GC/TV prevalence 
of 4.7/2.2/8.4%, increasing CT/GC screening uptake by 10% and adding 
simultaneous TV screening has an incremental cost per additional STI detected 
over a 5-year, 7-year, and lifetime time horizon of $376.18, $272.26, and $30.01, 
respectively. The incremental cost per adverse event avoided was $2,239.00, 
$1,541.86, $182.22, respectively. Lifetime adverse events avoided (discounted) 
include: 215 cases of PID, 93 PID-related sequelae, 14 adverse pregnancy 
outcomes and 0.8 HIV cases. CONCLUSIONS: Given its high prevalence, high rate 
of asymptomatic cases and the severity of the health consequences, TV should 
be considered as part of a comprehensive STI screening strategy. Increasing 
targeted screening for CT/GC/TV could be a cost-effective way of improving 
women’s health and a health plan’s quality of care.  
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RANDOMIZED CLINICAL TRIAL  
Pizzi LT1, Seligman N2, Baxter J3, Jutkowitz E4, Prioli KM1, Mearns E5, Berghella V3 
1Thomas Jefferson University, Philadelphia, PA, USA, 2University of Rochester Medical Center, 
School of Medicine and Dentistry, Rochester, NY, USA, 3Jefferson Medical College, Philadelphia, 
PA, USA, 4University of Minnesota, Minneapolis, MN, USA, 5Jefferson School of Pharmacy, 
Philadelphia, PA, USA  
OBJECTIVES: Preterm birth (PTB) is a costly public health problem that causes 
significant neonatal morbidity and mortality. To determine cost-effectiveness of 
vaginal progesterone (VP) gel in the prevention of preterm birth (PTB), we 
developed a decision analytic model using data from the PREGNANT trial. 
METHODS: PREGNANT was a multi-center, international RCT in which 459 
women with singleton gestations and short cervix (10-20mm by transvaginal 
ultrasound) were randomized to daily VP 8% gel (n=235) or placebo (n=224). 
Patient-level trial data along with cost data from the literature were used to 
develop the model (TreeAge Pro 2011). Births were categorized by gestational age 
at delivery: PTB at <28 weeks, PTB at 28-31 weeks, PTB at 32-36 weeks, or full 
term (≥37 weeks). Costs ($US 2011) included cervical length screening, VP gel 
(treatment group only), antenatal hospitalizations, cerclage, and delivery 
hospitalization (maternal + neonatal costs). The main outcome measure was 
incremental cost-effectiveness, calculated as the difference in total costs 
between the VP gel group and the placebo group, divided by the difference in the 
number of PTB averted between the VP gel group and the placebo group. A 
probabilistic sensitivity analysis (PSA) with 10,000 simulations was used to 
determine cost-effectiveness when both cost and outcome data were varied 
within defined limits. RESULTS: Model base case incremental savings for VP 
were $12,354 and an incremental benefit of VP was 0.042 PTB averted 
(ICER=$21,063/PTB averted). The PSA indicated that VP gel is expected to be less 
costly and more effective than placebo in 79.2% of simulated cases, however, less 
costly but ineffective in 16.8% of simulated cases. CONCLUSIONS: VP gel is cost-
effective in the prevention of PTB in women with short cervix as compared to 
placebo in most cases. Results inform ongoing clinical controversies regarding 
the value of VP as a preventive modality for PTB.  
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OBJECTIVES: LNG-IUS-12 is a low-dose hormonal intrauterine contraceptive 
system for up to 3 years of use. This analysis aimed to evaluate the cost-
effectiveness of LNG-IUS-12 in comparison to short-acting reversible 
contraceptive (SARC) methods in a cohort of young women in the United States 
(US) from a third-party payer’s perspective. METHODS: A state-transition model 
was developed to assess cost-effectiveness of LNG-IUS-12 versus SARC methods 
over 3 years in 1000 women aged 20-29 years, the age group accounting for over 
half of all abortions in the US. SARC methods comprise of oral contraceptives, 
ring, patch and injections – methods commonly used by this cohort. The model 
consisted of three mutually exclusive health states: initial method, unplanned 
pregnancy (UP) and subsequent method. Subsequent method is represented by a 
mixed market-weighted contraceptive ‘basket’. Failure and discontinuation rates 
were based on published literature. Unit costs were taken from standard US 
databases. Cost and effectiveness metrics for SARC were weighted using market 
share data. The key model output was cost per UP avoided. One-way sensitivity 
analyses (OWSA) and probabilistic sensitivity analyses (PSA) were performed. 
RESULTS: LNG-IUS-12 dominated SARC, resulting in fewer UP (65.26 vs. 278.97) 
and lower total costs ($1,274,295USD vs. $1,822,836USD, a 43% saving) over 3 
years. The costs associated with subsequent method used by women who 
initiated LNG-IUS-12 were lower ($107,587USD vs. $230,024USD) due to lower 
failure and discontinuation rates of LNG-IUS-12. OWSA results were insensitive 
to variation in key input parameters. PSA results indicate a high probability of 
dominance as all iterations were less costly and more effective. CONCLUSIONS: 
From a third-party payer perspective, LNG-IUS-12 is a more cost-effective 
contraceptive option than SARC. Therefore, women switching from current SARC 
use to LNG-IUS-12 are likely to generate cost savings to third-party health care 
payers, driven principally by decreased UP-related expenditures and long-term 
savings in contraceptive costs.  
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OBJECTIVES: About 30% of all pregnancies end in first trimester and half of them 
present as an incomplete miscarriage. It is a significant health issue raising 
economic burden on the publicly funded health care system in the Bahamas. 
Surgical evacuation is the most commonly used treatment which involves 
operating theater and inpatient costs in cases of complications like cervical 
trauma, uterine perforation, hemorrhage and infection. The objective of this 
study was to conduct a cost effectiveness analysis (CEA) of medical management 
(Misoprostol) versus surgical procedure in the management of incomplete 
miscarriages in the Bahamas, from a societal perspective. METHODS: Cost and 
probabilities of outcomes were derived from the hospital data and published 
literature. Cost of medical and surgical management included direct & indirect 
costs viz. physician cost, procedure cost, cost of ultrasounds, drug cost, cost of 
hospital stay, complications & adverse events; loss of wages and cost of travel. 
Primary outcomes were treatment success and failure. A one way sensitivity 
analyses were conducted by varying the cost and success by 25% & 15%, 
respectively. RESULTS: The CEA showed that, medical management (US$719 per 
patient) was the least costly alternative to surgical procedure (US$2,135 per 
patient). The incremental cost effectiveness ratio (ICER) of medical management 
was - $1,416 and proved to be the dominant option being less expensive and 
having comparable treatment success. Results were sensitive to variations in 
costs by 25% and success rate by 15% indicating domination of medical 
management suggesting being less expensive both to the patient as well as to 
the payer. CONCLUSIONS: From a societal perspective, medical management 
appears to be the least costly approach for the treatment of incomplete 
miscarriages in the Bahamas; and should be considered as the first line 
management. Further investigations are needed to obtain costs savings on long 
term horizon.  
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1Fundacion Salutia, Bogota, Colombia, 2Clinica de la Mujer, Bogota, Colombia  
OBJECTIVES: To evaluate the cost-effectiveness of levonorgestrel-releasing 
intrauterine system (LNG-IUS) as a long-term contraceptive method compared 
with similar methods, from the state perspective METHODS: A Markov chain 
model is developed to evaluate pregnancies avoided as outcome of interest. The 
model was built in monthly cycles at a five-year time horizon for a hypothetical 
cohort of 1,000 women of childbearing age and includes probabilities of 
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pregnancy, ectopic pregnancy, suspension because bleeding and other causes, 
and other adverse events by using either LNG-IUS, etonogestrel Implants, 
levonorgestrel implants or copper T (last-two included in health care plan). 
Effectiveness, adverse events and adherence were taken from previously 
published studies and the costs were taken from database of patients in 
Colombia and are expressed in Colombian pesos (COP). An expert gynecologist 
reviewed data. Threshold was estimated in $6.823.583 by calculating the costs 
assigned by the public health care system in Colombia to health care during the 
first five years of life of children and cost of delivery care. A sensitivity analysis 
was developed using a Montecarlo simulation and a Tornado analysis. RESULTS: 
TOTAL OF 13.87 pregnancies occurred with using LNG-IUS as compared with 
40.39 using Copper T, 30.08 using etonorgestrel implant, and 29.55 using 
levonorgestrel implant for the base case analyzed. Cost of LNG-IUS arm was 
COP$ 633,747,545 compared with copper T (COP$ 456,638,680), the less expensive. 
Applying a discount rate of 3% LNG-SIU was dominant versus implant 
etonogestrel and very cost-effective compared with levonorgestrel implant (ICER 
$631,682.98) and cost-effective compared with Copper T (ICER COP$ 6,678,395.53). 
Sensitivity analyses confirm that LNG-UIS keeps its benefits against etonogestrel 
and levonorgestrel in most cases. CONCLUSIONS: The use of LNG-IUS would be 
an adequate option for patients seeking a long-acting contraceptive method and 




COST-EFFECTIVENESS OF PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS 
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OBJECTIVES: Infection due to respiratory syncytial virus (RSV) is usually 
transient and leaves no sequelae; however, in infants with risk factors such as 
prematurity, bronchopulmonary dysplasia, congenital heart disease or 
infections, it can be more severe, and imply higher costs. Some observational 
studies support the likelihood of an association between RSV and asthma. 
According to the Colombian Medical Federation, palivizumab was one of the ten 
most expensive drugs for the Colombian health system (US$43.6 million in the 4-
year period 2008-11). The aim of this study was to evaluate the cost-effectiveness 
of palivizumab for the treatment of RSV infections in pre-term (<35 weeks) 
infants in Colombia. METHODS: We designed a decision tree model using local 
epidemiological data, effectiveness and safety, as well as QALYs, obtained from 
the scientific literature. We used the third-party payer perspective and a 3% 
discount rate for costs and long term outcomes. The time horizon was the 
lifetime of the patient. RESULTS: In our base case model, compared with no 
prophylaxis palivizumab showed on average an increase in costs per child of 
US$4.895, with 0.1645 QALYs gained, resulting in an incremental cost-
effectiveness ratio of US$29.760 per QALY (our per capita GDP is US$6723). Other 
outcomes of importance in the model were: US$359.962 per asthma case averted, 
US$1.087.884 per life saved and US$75.084 per hospitalization averted. The price 
of paliviumab should be decreased 32% to reach the cost-effectiveness threshold 
of 3-times the per capita GDP. CONCLUSIONS: Under the assumptions and 
results of our study, palivizumab is not a cost-effective intervention and should 
not be recommended for routine immunization in preterm infants of 35 weeks 




COST MINIMIZATION COMPARISON OF DARUNAVIR + RITONAVIR (DRV+RTV) 
TO LOPINAVIR/RITONAVIR (LPV/R) IN HIV-1 INFECTED TREATMENT-NAÏVE 
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OBJECTIVES: HIV guidelines consider LPV/r a preferred protease inhibitor for use 
during pregnancy. The budget implications of proactively initiating LPV/r versus 
initiating DRV+RTV and then potentially switching to LPV/r upon pregnancy 
were examined. METHODS: A cost minimization analysis was performed (US 
health care perspective) for HIV-1 infected, treatment-naïve WOCBA comparing: 
initiating LPV/r versus initiating DRV+RTV and switching to LPV/r when 
pregnant. A discrete event simulation was employed to represent antiretroviral 
(ARV) therapy management. Clinical trial data were used to model pregnancy 
rates, ARV switch rates, treatment impact as a function of CD4-cell count/viral 
load, adherence, treatment response, acquired resistance mutations, and 
treatment changes. Five- and 10-year costs incurred due to ARV therapy, clinical 
management of AIDS-related, non-AIDS related, and cardiovascular events were 
estimated. Analysis assumptions: switching to LPV/r can occur only once at first 
pregnancy, women’s medication adherence improves 15% at pregnancy and to 
100% if viral rebound. Analyses varied the rate of switching to LPV/r at time of 
pregnancy (0%, 30%, 100%), pregnancy rates, adherence improvement, and 
health care costs. Daily drug cost (WAC): LPV/r + TDF/FTC, $56.59; 
DRV+RTV+TDF/FTC, $73.89. Costs were discounted 3% per annum. RESULTS: 
With 0% switch, survival was similar for LPV/r and DRV+RTV, 7.68 and 7.69 life 
years, respectively (+/- 0.03 QALYs) at 10 years. Five- and 10-year health care 
costs of ARV-naïve WOCBA who initiate LPV/r were $107,790 and $192,352 per 
patient, respectively, versus $132,694 and $235,854 when initiating DRV+RTV (a 
$43,502 per patient savings at 10 years). If 100% of patients who initiated 
DRV+RTV switched to LPV/r upon pregnancy, savings per patient were reduced 
21.3%. Sensitivity analyses showed that initiating LPV/r was always cost-saving 
relative to DRV+RTV. CONCLUSIONS: Initiating HIV infected, treatment-naïve 
WOCBA on LPV/r was cost saving compared to initiating DRV+RTV. Analysis 
limitations include the uncertainty of long-term outcomes projections driven by 
short-term clinical trial endpoints.  
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OBJECTIVES: Labor induction has increasingly been used in the management of 
obstetrical care, owed to post-term pregnancies, maternal/fetal complications 
and voluntary election. Several cervical ripening and induction agents are 
available, though failure or complications with administration of current agents 
are common. Induction failure generally necessitates either additional induction 
agents and/or an eventual cesarean section. This analysis descriptively 
quantifies the economic burden associated with failed medical inductions 
among US Commercial and Medicaid patients. METHODS: A retrospective 
analysis of inpatient hospital discharge data for 2010, using the Healthcare Cost 
and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) was 
performed, to identify delivery stays with primary or secondary diagnoses of 
failed medical induction (ICD9 659.10-659.13). Rates of cesarean and vaginal 
delivery, average medical charges (converted to costs and displayed in 2010 USD) 
and length of stay per patient are provided. RESULTS: Failed labor induction 
discharges totaled 41,600 in 2010. The average cost for a vaginal delivery (with or 
without complications) after failed induction was $5,890 (average charges of 
$17,645) this is compared to average cost of $3,860 (average charges of $10,106) 
for all vaginal deliveries. Hospital cost for cesareans after failed induction 
averaged $7,595 (average charges of $28,700) compared to $5,990 (average 
charges of $21,875) for all cesarean sections. Average length of stay for failed 
induction with cesarean was 4.42, compared to 3.8 days with vaginal deliveries 
post-induction failure. CONCLUSIONS: Failed medical induction is associated 
with increased risk of cesarean delivery, and associated increased hospital 
resource use, and expenditure in delivery. Preventing complications with 
induction may substantially reduce health care costs and resource utilization.  
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OBJECTIVES: Cost-related medication non-compliance (CRN) is a persistent issue 
that negatively impacts the effectiveness of medical intervention. This study 
aims to evaluate the variation of CRN with functional deficiencies and with 
frequency of hospitalization among the US elderly using a nationally 
representative data set. METHODS: Health Retirement Survey (HRS) 2010 was 
used to assess CRN, deficiencies in Activities of Daily Living (ADL), Instrumental 
Activities of Daily Life (IADL), and frequency of hospitalization over the past 2 
years (0, 1, 2, 3, or 4 or more). CRN was assessed based upon self-reported non-
compliance. After performing bivariate analyses of the association between 
ADLs/IADLs, hospitalizations, insurance coverage, self-reported monthly out-of-
pocket (OOP) payments of prescription drugs and CRN, a logit model was used to 
assess the relationship between CRN and associated risk factors. RESULTS: 2,793 
(12.7%) out of 22,042 elderly reported CRN over a period of 2 years. Those 
reported CRN has a mean ADL deficiencies 0.79 (s.d. 1.43) versus those who did 
not 0.48 (s.d. 1.16) (p<0.001), and a mean IADL deficiencies 0.53 (s.d. 0.97) versus 
those who did not 0.38 (s.d. 0.92) (p<0.001). The logit model showed that 
compared to those who did not have hospitalization, those who had 1 admission 
were 17% more likely to report CRN (p=0.005), those with 2 admissions 14% more 
likely (p=0.10), 3 admissions 54% more likely (p<0.001), and 4 or more admissions 
33% more likely to report CRN (p=0.007). There was an inverse U-shaped 
relationship between CRN and deficiencies in ADLs/IADLs; as ADL/IADL 
deficiencies increased, the likelihood of CRN first increased and then decreased. 
CONCLUSIONS: The positive relationship between number of hospitalization and 
CRN and the inverse U-shaped relationship between functional deficiencies and 
CRN raise concerns that CRN may decrease the effectiveness and increase the 
cost of care in this population.  
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OBJECTIVES: The Women’s Health Initiative (WHI) estrogen+progestin (E+P) 
clinical trial provides a large sample to estimate health state utility values for 
post-menopausal women with an intact uterus in the United States. To facilitate 
future health economic evaluations in this large population sub-group, we 
estimated utilities for trial participants stratified by age group (50-59, 60-69, 70-
79) and randomization assignment (E+P or placebo). METHODS: We measured 
health state utility values for all 16,608 trial participants with the Short Form-6D 
(SF-6D) utility index using a validated Bayesian mapping algorithm and U.S. 
weights. We calculated cross-sectional mean baseline and 1-year utilities, and 
mean within-patient utility change from baseline to 1-year. Patients included in 
the baseline analysis completed the SF-36 within 7 days of randomization, and 
